Customizable Platform Technology
Enables High Affinity Monoclonal
Antibody Discovery
Isolated antibodies possess much greater drug binding and selectivity compared to previous efforts in the scientific literature
Pharmacokinetics of free drug
Substances of abuse (such as fentanyl, nicotine, THC, ect.) pass through the blood-brain barrier and enter the central nervous system (CNS), where it interacts with receptors to cause psychotropic and potentially dangerous effects.
Pharmacokinetics of drug-specific antibody
Our antibody therapy binds tightly to the substance of abuse in the bloodstream, preventing it from getting into the CNS and exerting its harmful and psychotropic effects.
Pharmacokinetics of drug-specific antibody
Our antibody therapy binds tightly to the substance of abuse in the bloodstream, preventing it from getting into the CNS and exerting its harmful and psychotropic effects.
Monoclonal antibodies sequester the substance of abuse in the bloodstream, preventing it from affecting the brain. The use of monoclonal antibodies allows for tight control of dosing as well as providing immediate protection after treatment. The monoclonal antibody is restricted to the blood stream, and thus not likely to have abuse potential of its own or to induce psychiatric side-effects common to other treatments for substance use disorders.
Fentanyl Program
Nicotine Program
THC Program
Preclinical
CMC & Tox
Phase I
Phase II
CSX-1004 is a human monoclonal antibody directed against fentanyl and fentanyl analogs. It is being developed as an IV infusion product that will offer immediate protection and last for at least 30 days. Phase 1 clinical trials of the CSX-1004 IV infusion are expected to commence in June 2023 to examine safety, pharmacokinetics and immunogenicity of CSX-1004 in healthy human subjects.
CSX-1004 is a monoclonal antibody directed against fentanyl and fentanyl analogs. A fixed-dose injectable subcutaneous (SQ) formulation of CSX-1004 is being developed that would offer the same longevity of protection as the IV infusion and can be conveniently administered at multiple points of care.
CSX-1100 is an antibody fragment based on CSX-1004. This molecule is being developed for use in an autoinjector format as a rapidly deployable countermeasure against fentanyl exposure to enable prevention or treatment of fentanyl overdose in the field.
CSX-3002 is a monoclonal antibody being developed for the treatment of nicotine addiction. We have generated several high-affinity antibodies to nicotine, which are able to block nicotine’s effects in mice. Current studies are examining the efficacy of CSX-3002 in disrupting the behavioral effects of nicotine in rats.
Cessation is currently investigating several monoclonal antibody candidates against THC as well as synthetic cannabinoids. Antibodies generated in this program would offer treatment of acute overdose for which there is currently no approved medications.